Janux therapeutics appoints winston kung to board of directors

San diego--(business wire)---- $janx--janux therapeutics, inc. (nasdaq: janx) (janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its tumor activated t cell engager (tractr) and tumor activated immunomodulator (tracir) platforms, today announced the appointment of winston kung to the company's board of directors. janux also announced that stefan heller, ph.d., who has served on janux's board since 2018, has resigned. these ch
JANX Ratings Summary
JANX Quant Ranking